

Zydus gets approval for antihistamine drug

23 May 2017 | News

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Cyproheptadine Hydrochloride tablets in the strength of 4 mg.



Drug firm Zydus Cadila has received approval from the US health regulator to market antihistamine Cyproheptadine Hydrochloride tablets in the US market.

The company has received final approval from the United States Food and Drug Administration (USFDA) to market Cyproheptadine Hydrochloride tablets in the strength of 4 mg. The tablets are used to relieve allergy symptoms such as hives, watery eyes, sneezing and itching eyes or nose

The drug will be produced at the group's formulation manufacturing facility at the pharma SEZ in Ahmedabad. The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs).